ArticleBritish journal of cancer2012
Serum biomarker panels for the diagnosis of gastric adenocarcinoma.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Advances in protein microarray-based proteomics for gastric cancer applications in biomarker discovery, molecular subtyping, and precision oncology.Frontiers in oncology · 2026Review
- Serum metabolic profiling analysis of chronic gastritis and gastric cancer by untargeted metabolomics.Annals of medicine and surgery (2012) · 2025Article
- Proteomics appending a complementary dimension to precision oncotherapy.Computational and structural biotechnology journal · 2024Review
- Explainable machine learning models for early gastric cancer diagnosis.Scientific reports · 2024Article
- PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy.Discover oncology · 2024Article
- Painless and sensitive pepsinogen I detection: an electrochemical immunosensor based on rhombic dodecahedral CuNanoscale advances · 2022Article
- Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening.Obstetrics & gynecology science · 2022Article
- Multiplexed measurement of candidate blood protein biomarkers of heart failure.ESC heart failure · 2021Article
- Article
- Proteomics and phosphoproteomics in precision medicine: applications and challenges.Briefings in bioinformatics · 2019Review
- Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer.Oncology letters · 2019Article
- The expansion of targetable biomarkers for CAR T cell therapy.Journal of experimental & clinical cancer research : CR · 2018Review
- Interleukins 17 and 23 in patients with gastric neoplasms.Scientific reports · 2016Article
- Potential Diagnostic, Prognostic and Therapeutic Targets of MicroRNAs in Human Gastric Cancer.International journal of molecular sciences · 2016Review
- Elevated level of some chemokines in plasma of gastric cancer patients.Central-European journal of immunology · 2016Article
- Identification of cysteinylated transthyretin, a predictive biomarker of treatment response to partially hydrolyzed guar gum in type 2 diabetes rats, by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.Journal of clinical biochemistry and nutrition · 2016Article
- Emerging blood-based biomarkers for detection of gastric cancer.World journal of gastroenterology · 2015Review
- Challenges of deciphering gastric cancer heterogeneity.World journal of gastroenterology · 2015Review
- Expression analysis of apolipoprotein E and its associated genes in gastric cancer.Oncology letters · 2015Article
- Implementation of gastric cancer screening - the global experience.Best practice & research. Clinical gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, serum biomarkers, which are sufficiently sensitive and specific for early detection and risk classification of gastric adenocarcinoma do not exist. Therefore, this study identified a panel of serum biomarkers for the diagnosis of gastric adenocarcinoma.
methodsA 29-plex array platform with 29 biomarkers, consisting of 11 proteins discovered through proteomics and 18 previously known to be cancer-associated, was constructed. A test/training set consisting of 120 gastric adenocarcinoma and 120 control samples were examined. After 13 proteins were selected as candidate biomarkers, multivariate classification analyses were used to identify algorithms for diagnostic biomarker combinations. These algorithms were independently validated using a set of 95 gastric adenocarcinoma and 51 control samples.
resultsEpidermal growth factor receptor (EGFR), pro-apolipoprotein A1 (proApoA1), apolipoprotein A1, transthyretin (TTR), regulated upon activation, normally T-expressed and presumably secreted (RANTES), D-dimer, vitronectin (VN), interleukin-6, α-2 macroglobulin, C-reactive protein and plasminogen activator inhibitor-1 were selected as classifiers in the two algorithms. These algorithms differentiated between the majority of gastric adenocarcinoma and control serum samples in the training/test set with high accuracy (>88%). These algorithms also accurately classified in the validation set (>85%).
conclusionTwo panels of combinatorial biomarkers, including EGFR, TTR, RANTES, and VN, are developed, which are less invasive method for the diagnosis of gastric adenocarcinoma. They could supplement clinical gastroscopic evaluation of symptomatic patients to enhance diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.